Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | HRAS Q61L |
Therapy | AZD8055 + Binimetinib |
Indication/Tumor Type | lung squamous cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
HRAS Q61L | lung squamous cell carcinoma | sensitive | AZD8055 + Binimetinib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Binimetinib (MEK162) and AZD8055 reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture (PMID: 26544513). | 26544513 |
PubMed Id | Reference Title | Details |
---|---|---|
(26544513) | Mutant HRAS as novel target for MEK and mTOR inhibitors. | Full reference... |